January 25, 2019
TUESDAY, January 22, 2019 (TIME magazine)—DNA testing company 23andMe Inc. said it has gotten the green light from the U.S. Food and Drug Administration to offer consumers a test for a hereditary colorectal cancer syndrome.
23andMe said it will now be able to tell customers whether they have two genetic variants that influence MUTYH-associated polyposis, a rare condition associated with an increased risk of colorectal cancer. The FDA didn’t immediately respond to a request for comment.
NOTE: The Prevent Cancer Foundation® advises anyone considering this form of genetic testing to consult with a health care professional, as receiving a negative result may give you a false sense of your cancer risk. Read our full statement.
Shutdown Poses Risk to Health Care
Jan. 23, Dow Jones
America’s original tobacco state considers raising the smoking and vaping age to 21
Jan. 20, The Washington Post
To Fight Fatty Liver, Avoid Sugary Foods and Drinks
Jan. 22, The New York Times